Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 63 of 116

  1. Obatoclax Mesylate

    Teva Pharma GmbH

    Metastatic Melanoma

    phase 2 small molecule terminated

    1 trial

  2. Obatoclax mesylate

    Teva Pharma GmbH

    Lymphoma, Follicular

    phase 2 small molecule completed

    1 trial

  3. Obatoclax mesylate

    Teva Pharma GmbH

    Mantle-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  4. Obatoclax mesylate (GX15-070MS)

    Teva Pharma GmbH

    Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  5. Obatoclax mesylate 250 ml

    Teva Pharma GmbH

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  6. Obecabtagene Autoleucel

    Autolus GmbH

    Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  7. Obecabtagene autoleucel

    Autolus GmbH

    Acute Lymphocytic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  8. Obinutuzumab

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  9. Obinutuzumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial

  10. Obinutuzumab

    Adaptive Biotechnologies Corp

    Mantle Cell Lymphoma

    phase 2 mab active

    1 trial

  11. Odomzo 200 mg hard capsules

    Fondazione Telethon ETS

    locally advanced basal cell carcinoma

    phase 2 small molecule active

    1 trial

  12. Odronextamab

    Regeneron UK Limited

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 2 mab active

    1 trial

  13. Odronextamab

    Regeneron UK Limited

    B-cell Non-Hodgkin Lymphoma (B-NHL)

    phase 2 small molecule active

    2 trials

  14. Odronextamab

    Regeneron UK Limited

    Follicular Lymphoma

    phase 2 mab active

    1 trial

  15. Olaparib

    United Therapeutics Europe Ltd

    Bile Duct Adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. Olaparib Continuous (28-Day cycle) 300 mg BD.

    AstraZeneca

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  17. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Chronic Myelomonocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  18. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  19. Olverembatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    phase 2 small molecule completed

    1 trial

  20. Olverembatinib

    The First People's Hospital of Lianyungang

    Myeloproliferative Neoplasm

    phase 2 small molecule active

    1 trial

  21. OlympiaN

    AstraZeneca AB

    BRCA Mutations and Early Stage HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  22. Omacetaxine

    Teva Pharma GmbH

    Leukemia

    phase 2 small molecule terminated

    2 trials

  23. Omacetaxine

    Teva Pharma GmbH

    Acute Myelogenous Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  24. Omacetaxine mepesuccinate

    Teva Pharma GmbH

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    3 trials

  25. Ommaya 02

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastasis of HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  26. Omomyc

    The George Institute

    Advanced High-Grade Osteosarcoma

    phase 2 small molecule active

    1 trial

  27. Onapristone

    Context Therapeutics

    ER-positive Breast Cancer

    phase 2 small molecule terminated

    1 trial

  28. Onapristone ER

    Context Therapeutics

    Granulosa Cell Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  29. Onvansertib

    Cardiff Oncology

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  30. Onvansertib

    Cardiff Oncology

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  31. Onvansertib

    Cardiff Oncology

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  32. Onvansertib

    Cardiff Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  33. Onvansertib

    Cardiff Oncology

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  34. Onvansertib

    Cardiff Oncology

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  35. Onvansertib

    Cardiff Oncology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  36. Onvansertib

    Cardiff Oncology

    Breast Cancer

    phase 2 small molecule active

    1 trial

  37. Oral Encochleated Amphotericin B (CAMB)

    Matinas BioPharma Holdings

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  38. Oral arsenic trioxide

    The University of Hong Kong

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  39. Orelabrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  40. Orelabrutinib

    The First People's Hospital of Lianyungang

    MALT Lymphoma

    phase 2 small molecule active

    1 trial

  41. Orelabrutinib

    The First People's Hospital of Lianyungang

    Marginal Zone Lymphoma(MZL)

    phase 2 small molecule active

    1 trial

  42. Orelabrutinib

    The First People's Hospital of Lianyungang

    Primary Central Nervous System Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  43. Orelabrutinib

    The First People's Hospital of Lianyungang

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  44. Organoid-guided treatment

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  45. Orgovyx 120 mg film-coated tablets

    Fondazione Telethon ETS

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  46. Orteronel 300mg BID

    Takeda

    Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors

    phase 2 small molecule terminated

    1 trial

  47. Osimertinib + Savolitinib

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  48. Osimertinib 80 mg/40 mg

    AstraZeneca

    Stage II-IIIB Non-small Cell Lung Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.